These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21672909)

  • 1. Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.
    Chen JL; Li J; Stadler WM; Lussier YA
    J Am Med Inform Assoc; 2011; 18(4):392-402. PubMed ID: 21672909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein interaction network underpins concordant prognosis among heterogeneous breast cancer signatures.
    Chen J; Sam L; Huang Y; Lee Y; Li J; Liu Y; Xing HR; Lussier YA
    J Biomed Inform; 2010 Jun; 43(3):385-96. PubMed ID: 20350617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
    Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
    JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer.
    Cooperberg MR; Erho N; Chan JM; Feng FY; Fishbane N; Zhao SG; Simko JP; Cowan JE; Lehrer J; Alshalalfa M; Kolisnik T; Chelliserry J; Margrave J; Aranes M; Plessis MD; Buerki C; Tenggara I; Davicioni E; Carroll PR
    Eur Urol; 2018 Oct; 74(4):444-452. PubMed ID: 29853306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
    Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
    Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
    Ross-Adams H; Lamb AD; Dunning MJ; Halim S; Lindberg J; Massie CM; Egevad LA; Russell R; Ramos-Montoya A; Vowler SL; Sharma NL; Kay J; Whitaker H; Clark J; Hurst R; Gnanapragasam VJ; Shah NC; Warren AY; Cooper CS; Lynch AG; Stark R; Mills IG; Grönberg H; Neal DE;
    EBioMedicine; 2015 Sep; 2(9):1133-44. PubMed ID: 26501111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.
    Mo F; Lin D; Takhar M; Ramnarine VR; Dong X; Bell RH; Volik SV; Wang K; Xue H; Wang Y; Haegert A; Anderson S; Brahmbhatt S; Erho N; Wang X; Gout PW; Morris J; Karnes RJ; Den RB; Klein EA; Schaeffer EM; Ross A; Ren S; Sahinalp SC; Li Y; Xu X; Wang J; Wang J; Gleave ME; Davicioni E; Sun Y; Wang Y; Collins CC
    Eur Urol; 2018 Apr; 73(4):524-532. PubMed ID: 28330676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression.
    Luca BA; Moulton V; Ellis C; Connell SP; Brewer DS; Cooper CS
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32708551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression.
    Chen JL; Li J; Kiriluk KJ; Rosen AM; Paner GP; Antic T; Lussier YA; Vander Griend DJ
    Clin Cancer Res; 2012 Aug; 18(16):4291-302. PubMed ID: 22723371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
    Glinsky GV
    Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
    Jin Y; Wang L; Lou H; Song C; He X; Ding M
    Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
    Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
    Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.
    Bian Z; Huang X; Chen Y; Meng J; Feng X; Zhang M; Zhang L; Zhou J; Liang C
    Int J Med Sci; 2021; 18(1):284-294. PubMed ID: 33390797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the prognostic significance of IKKα in prostate cancer.
    Montes M; MacKenzie L; McAllister MJ; Roseweir A; McCall P; Hatziieremia S; Underwood MA; Boyd M; Paul A; Plevin R; MacKay SP; Edwards J
    Prostate; 2020 Oct; 80(14):1188-1202. PubMed ID: 33258506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer.
    Planche A; Bacac M; Provero P; Fusco C; Delorenzi M; Stehle JC; Stamenkovic I
    PLoS One; 2011; 6(5):e18640. PubMed ID: 21611158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular classification of prostate cancer using curated expression signatures.
    Markert EK; Mizuno H; Vazquez A; Levine AJ
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21276-81. PubMed ID: 22123976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.
    Zhao SG; Evans JR; Kothari V; Sun G; Larm A; Mondine V; Schaeffer EM; Ross AE; Klein EA; Den RB; Dicker AP; Karnes RJ; Erho N; Nguyen PL; Davicioni E; Feng FY
    Clin Cancer Res; 2016 Apr; 22(7):1777-86. PubMed ID: 26631616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic signatures associated with the development, progression, and outcome of prostate cancer.
    Mendiratta P; Febbo PG
    Mol Diagn Ther; 2007; 11(6):345-54. PubMed ID: 18078352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.